Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acquisition
Biotech
Xoma adds another struggling biotech to its buyout roster
After Generation Bio telegraphed major layoffs this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold.
Fraiser Kansteiner
Dec 16, 2025 11:00am
Cycle Pharma scoops up beleaguered rare disease biotech
Dec 12, 2025 9:55am
J&J pays $3B cash for Halda's cancer cell death tech
Nov 17, 2025 10:19am
Novo CEO tells Pfizer to 'bid higher' if it wants to win Metsera
Nov 7, 2025 10:00am
Publisher’s note: Questex acquires The Conference Forum, Versalinx
Nov 4, 2025 12:00pm
Cardiometabolic field drives M&A while cancer deals drop: report
Oct 27, 2025 2:39pm
